Alphabet GAAP EPS of $2.81 beats by $0.80, revenue of $90.23B beats by $1.08B Alphabet Inc., Google’s parent company, delivered a stellar Q1 2025 earnings report, showcasing robust financial performance. Revenue reached $90.23 billion, up 12% from $80.54 billion in Q1 2024, exceeding analyst expectations of $89.1 billion. Diluted earnings per share soared 49% to $2.81, surpassing forecasts of $2.01, driven by an $8b unrealised gain on non-marketable securities (stocks/investments). Operating income climbed 20% to $30.61 billion, with the operating margin expanding to 33.9% from 31.6%, reflecting disciplined cost management despite a 14% rise in R&D spending to $13.56 billion. Google Cloud was a standout, with revenue up 28% to $12.26 billion and operating margin nearly doubling to 17.8% from 9.4%. Alphabet announced a $70 billion share buyback programme and a $0.21 per share dividend, reinforcing shareholder returns. Capital expenditure was confirmed at $75 billion for 2025, a 43% increase from $52.5 billion in 2024, primarily for AI-driven infrastructure like servers and data centres, with $16–18 billion earmarked for Q1 alone. CEO Sundar Pichai attributed the strong results to Alphabet’s “unique full stack approach to AI,” highlighting breakthroughs with Gemini 2.5 and AI Overviews, which now serves 1.5 billion monthly users. CFO Anat Ashkenazi emphasised sustained investment in technical infrastructure to bolster cloud and AI capabilities, noting that costs grew slower than revenue, enhancing efficiency [image: 1745564682098-screenshot-2025-04-25-at-07.51.54.png] [image: 1745564695087-screenshot-2025-04-25-at-07.52.11.png]

Working tonight

Hi D, Netflix is set to drop its Q1 2025 earnings after the market shuts on 17 April. Analysts expect earnings per share (EPS) will hit $5.74, up 8.7% from $5.28 last year, with revenue expected at $10.54 billion, a 12.5% jump year-on-year. That’s pretty close to Netflix’s own forecast of $10.46 billion in revenue and an operating margin of 28.2%. They’ve got a history of smashing EPS forecasts, beating expectations in all four of the last reported quarters, like Q4 2024 when they pulled off $4.27 against $4.20 expected. That said, it's hard to know but their numbers should be solid. Everyone’s eyeing their ad-supported memberships, which made up 55% of sign-ups in ad markets last quarter, and their content line-up, with several content hits. They won’t disclose subscriber numbers anymore, focusing on revenue and margins instead.

Here is a complete list of ALL notable Robotics players. See the common thread? [image: 1744622289650-screenshot-2025-04-14-at-10.15.51.png]

SK hynix raises its 2025 CAPEX from $15 billion to $19 billion. SK Hynix has decided to increase its planned CAPEX this year by 30% due to the surge in demand for high-bandwidth memory (HBM), which was already high. The chipmaker initially planned to spend 22 trillion won this year in expanding its facilities but this has been upped to 29 trillion won, sources said. The decision was recently finalised and SK Hynix has also sent memos to suppliers to deliver the equipment to the M15X fab in Chungju by October, two months faster than initially planned. These moves are all responses from its customers requesting SK Hynix deliver more HBM chips faster. The company’s main customer is Nvidia, which is using HBM with its AI accelerators. The GPU giant is requesting SK Hynix deliver HBM faster than planned. SK Hynix will also be supplying HBMs to Broadcom starting this year. We are reading the room, folks. Demand is off the hook and I would speculate, supply is also improving. Whilst the market is distracted by and shunning everything due to tariffs speculation, these businesses are clearly articulating a shift.

Our main Pharma holding is Vertex. They have majority manufacturing presence in Boston, Massachusetts, where they use a cutting-edge continuous manufacturing facility for cystic fibrosis drugs like Trikafta. Their golden goose. Other companies: [image: 1744535569397-screenshot-2025-04-13-at-10.12.33.png]

Here is the compute comparison. One rack = the entire DC. The DC cost 3b usd to build and 150m annually to operate excluding the land/lease The single rack costs 30m and 12m to operate annually. Could live in a broom closet [image: 1742381904418-screen-shot-2025-03-19-at-10.52.08.png]

Thank you Nik. Perhaps you could propose giving the client the option to abandon the small change remaining in funds since it costs the company more to withdraw than the amounts themselves. This would help expedite the process. Frank

We will be making two changes to the portfolios next week(2 new stocks)-not sure of exact timing. Treat this as aheads up of an impending rebalance across Lifestyle/Tech

I'd expect significant tinkering with pension allowances and relief rates and some kind of cap on ISAs - possibly a cap on maximum lifetime contributions or a cap on allowed value after which you can't make any more contributions. Too many people have too much money for themselves and large numbers of people are in need of (more) state support, or so our political overlords think. The money therefore needs to be taken from the former and given to the latter.

@Ducati996R Hi Clive drop me a message nik.burrows@cobensdirect.co.uk Cheers

Hi Gents Apologies Dingg, I remember your suggestion and thought it was a good one and then didn't put the post up. As mentioned elsewhere we have a number of interface upgrades in place which will look to streamline a lot of the admin processes that we run and this should not only improve efficiency but should also see you get quicker turnarounds and more info along the way so you can track the progress of a request. That said in the meantime typically time lines are : ISA/GIA 5-7 working days this allows for sell down of the asset and transfer of funds to your nominated bank account Pension 4-6 weeks, This allows for the HMRC/Pay Roll process and then sell down of assets and transfer of funds to your nominated bank account Pension payments can on occasion be quicker but use the above as a guide

Ok sure, send it over

@Adam-Kay said in Dashboard performance charts.: J, I wish you’d mentioned this a while ago. [image: 1740153593731-screen-shot-2025-02-21-at-15.56.38.png] Crumbs. That's not shabby.

Great to hear Ron. That portfolio has been very productive. I’m very proud of it and very pleased for anyone who put their hard earned money into it.

@Renmure-Jim said in Remaining ISA allowance bug in the system?: I’ve taken advantage of the flexible ISA a couple of times for significant purchases within a tax year and found the withdrawing and repaying to be pretty simple and intuitive. I'll second this. Most ISA providers don't offer flexible ISA's (my previous ISA provider didn't even know what one was.) This was a major factor in me moving my ISA to IM a few years ago.

Thanks for the replies and sorry I missed your call earlier Adam. I'll give you a bell in the morning. Cheers all, have a good evening.

A solid result from Vertex, meeting expectations and guiding higher for the current year. The main focus being their newly approved pain therapy. Here are some notes taken from the conference call. It's a very big market and this drug will be a 'Blockbuster'-revenue greater than $1B and annually, once it gets known/established. We have a holding cost of $256. The current price is $470, as such the IC is very pleased with the company performance. Vertex has a bright future ahead of itself-improving patients qualify of life and earning shareholders healthy profits along the way. A win-win as they say. JOURNAVX in acute pain as we are currently 10 days post the milestone approval of this first selective, oral, non-opioid pain signal inhibitor. The approval is so critical because JOURNAVX represents the first new class of pain medicine in over 20 years. It combines effective pain relief with a favourable safety profile. And based on its MOA(mechanism of action), it does not have addiction potential. It is indicated for use across all types of moderate-to-severe acute pain. For example, post-surgery, broken bones, sports injuries and has the potential to establish a new standard of care for the 80 million patients, who seek a prescription therapy to treat moderate-to-severe acute pain each year in the U.S. Half of those seeking help for their acute pain or approximately 40 million Americans each year are prescribed opioids, which although effective have significant safety and tolerability concerns and addictive potential. In fact, tragically, an estimated 85,000 people each year will develop opioid use disorder within the first year of being prescribed an opioid for acute pain. We believe we now have the opportunity to transform how acute pain is treated in the U.S. and to build another multi-billion dollar franchise for Vertex. We are launch ready and have now begun commercialisation of JOURNAVX. Our focus for 2025 is to engage with healthcare professionals, decision-makers and payers to establish the conditions for rapid patient access that will deliver long-term commercial success for our pain franchise. To that end, while still just a few days into the launch, we believe that the incredibly broad positive media coverage JOURNAVX has received since approval is one measure of the high unmet need and an indication of the societal importance of providing both physicians and patients with a new non-opioid option for the treatment of acute pain. We've already seen tremendous interest and requests for information from both doctors and patients, and we look forward to being able to serve them. Our 150 person sales force is actively engaging with healthcare providers and physicians on the compelling efficacy and safety data of JOURNAVX and its role in all types of moderate-to-severe acute pain. In the institutional setting, we are engaging with roughly 2,000 high-volume hospitals and approximately 150 related health systems. We have line of sight to accelerate the typical P&T (pharmacy & therapeutics) committee processes in many networks to support the use of JOURNAVX in this setting. We are advancing our discussions with national and regional payers and group purchasing organisations to provide access to JOURNAVX, building on our work pre-approval to accelerate formula reviews and limit inappropriate utilization management controls. And lastly, with retail pharmacies, we are working to secure broad stocking agreements at national retail pharmacies and regional chains to ensure availability of JOURNAVX for patients across the country. We have also now begun our non-personal promotional initiatives to physicians and patients to promote broad awareness of the first, oral, non-opioid pain signal inhibitor for moderate-to-severe acute pain, such as embedded content in relevant websites like Medscape for physicians and WebMD for consumers, along with point-of-care marketing.

Touche, I would expect the main focus to be 'Jensen Huang sporting a Tom Ford lizard skin effect jacket which retails at £8,000 and recently purchased two new G650 jets which retail at £60M each before options'